Kerstjens H A, Postma D S, van Doormaal J J, van Zanten A K, Brand P L, Dekhuijzen P N, Koëter G H
Department of Pulmonology, University Hospital Groningen, The Netherlands.
Thorax. 1994 Jul;49(7):652-6. doi: 10.1136/thx.49.7.652.
Recent reports have suggested short-term changes in serum parameters of bone metabolism with inhaled corticosteroids. The relevance of these findings to the balance between bone formation and resorption during years of corticosteroid treatment remains uncertain.
Two novel markers of bone turnover were first compared with conventional markers in a pilot study and subsequently measured in a long-term double blind study of inhaled corticosteroids. In study I 15 patients were newly started on at least 800 micrograms inhaled corticosteroids daily. At entry and after four weeks serum levels of alkaline phosphatase, osteocalcin, and PICP (procollagen type I carboxy terminal propeptide; a procollagen splice product) were measured as markers of bone formation, as well as the urinary hydroxyproline/creatinine ratio and serum levels of ICTP (type I collagen carboxy terminal telopeptide; a collagen degradation product) as markers of bone resorption. In study II 70 patients with airways obstruction received 800 micrograms beclomethasone daily in addition to terbutaline and 85 received bronchodilators only in a double blind fashion. Serum levels of PICP and ICTP were measured before and after 2.5 years of treatment.
In study I a decrease in osteocalcin levels was accompanied by an increase in levels of PICP and a small and non-significant rise in alkaline phosphatase. There were no changes in hydroxyproline or ICTP. In study II no differences were found in serum levels of PICP between the treatment groups; an increase in serum ICTP was found in the group treated without inhaled corticosteroids compared with the group treated with inhaled corticosteroids.
No detrimental long-term effect of inhaled corticosteroids was found with three conventional and two novel parameters of bone metabolism. The results indicate that long-term changes in bone turnover during treatment with inhaled corticosteroids should not be deduced from short-term studies with single serum parameters of bone metabolism, but well designed long-term studies of, for example, bone densitometry should be awaited before quoting detrimental effects of inhaled corticosteroids on bone metabolism.
最近的报告显示吸入性糖皮质激素可使骨代谢的血清参数发生短期变化。然而,这些发现与多年糖皮质激素治疗期间骨形成和骨吸收平衡的相关性仍不明确。
在一项初步研究中,首先将两种新的骨转换标志物与传统标志物进行比较,随后在一项吸入性糖皮质激素的长期双盲研究中对其进行测量。在研究I中,15名患者开始每日至少吸入800微克糖皮质激素。在入组时和四周后,测量血清碱性磷酸酶、骨钙素和PICP(I型前胶原羧基末端前肽;一种前胶原剪接产物)水平作为骨形成标志物,以及尿羟脯氨酸/肌酐比值和血清ICTP(I型胶原羧基末端端肽;一种胶原降解产物)水平作为骨吸收标志物。在研究II中,70名气道阻塞患者除特布他林外,每日接受800微克倍氯米松治疗,8雾剂治疗。在治疗2.5年之前和之后测量血清PICP和ICTP水平。
在研究I中,骨钙素水平降低的同时PICP水平升高,碱性磷酸酶有小幅升高但无统计学意义。羟脯氨酸或ICTP无变化。在研究II中,治疗组之间血清PICP水平未发现差异;与吸入糖皮质激素治疗组相比,未接受吸入糖皮质激素治疗组的血清ICTP升高。
通过三个传统和两个新的骨代谢参数未发现吸入性糖皮质激素有长期有害影响。结果表明,不应从单一骨代谢血清参数的短期研究推断吸入性糖皮质激素治疗期间骨转换的长期变化,而在引用吸入性糖皮质激素对骨代谢的有害影响之前,应等待例如骨密度测量等精心设计的长期研究结果。